Koninklijke Philips N.V. NY Reg (PHG) Stock Price & How to Invest

Koninklijke Philips N.V. (Royal Philips) is a Netherlands-based health-technology company that generated roughly EUR 17.8 billion (about $19 billion) in 2025 sales across three segments: Diagnosis and Treatment (imaging systems, image-guided therapy, ultrasound), Connected Care (patient monitoring, hospital informatics, and its Respironics sleep and respiratory business), and Personal Health (electric shavers, toothbrushes, and mother-and-child care). US investors most commonly access it through the PHG American Depositary Receipt on the NYSE, which represents ordinary shares that also trade in Amsterdam; the ADR structure means currency moves between the euro and the dollar affect the quoted price and the dividend.

The investment picture is a turnaround. After exiting its lighting and appliance roots to become a pure health-technology company, Philips spent recent years absorbing the 2021 Respironics device recall, related US litigation, and softness in China. In 2025 it returned to a reported net income of about EUR 897 million and lifted its adjusted EBITA margin to 12.3 percent, and it entered 2026 reiterating guidance for 3 to 4.5 percent comparable sales growth and a 12.5 to 13.0 percent adjusted EBITA margin. Results in 2026 have run ahead of estimates on earnings while sales stay flat: second-quarter 2026 sales were about EUR 4.36 billion with net income of about EUR 384 million, and EPS of 0.56 compared with a 0.37 consensus, the fourth straight beat, while sales grew only about 0.5% year over year. Trailing twelve-month sales were about EUR 17.7 billion and net income about EUR 1.1 billion. On October 10, 2026 the Enterprise Chamber of the Amsterdam Court of Appeal dismissed a request by shareholders, including the Dutch investors' association VEB, for an investigation into how Philips handled the Respironics recall, finding no sufficient grounds to question its policies or management. In October Philips also launched cardiovascular clinical studies across Europe with the EXIT-CVD research consortium. The story now hinges on whether order intake and margin gains can compound while the China market and legacy risks normalize.

China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. The 2021 Respironics recall led to large US litigation; a roughly $1.1 billion personal-injury settlement and a medical-monitoring class-action resolution have reduced but not fully eliminated legal and reputational overhang; the October 2026 Amsterdam ruling rejecting a shareholder request for an inquiry into the recall removes one more strand. Tariffs and cost inflation pressure margins and partly offset productivity gains. As an ADR of a euro-reporting company, US investors bear currency risk between the euro and the dollar on both price and dividends. Competition from larger and well-capitalized rivals in imaging can pressure pricing and market share. Top-line growth is the other open question: sales grew only about 0.5% year over year in Q2 2026, and consensus for Q3 EPS (0.36) is about 13% below a year earlier.

5 analysts publish price targets on PHG, averaging $32.02 against a $25.74 price as of October 2026, or +24.4%. The published targets run from $26.20 to $41.00, a moderate spread, and the ratings split 2 buy, 3 hold, 0 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PHG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Koninklijke Philips N.V. NY Reg. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin recovery and cost discipline. Philips lifted its adjusted EBITA margin to 12.3 percent in 2025 and guides to 12.5 to 13.0 percent for 2026, driven by productivity savings, an innovation-led gross margin, and a leaner cost base. The most optimistic published target, $41.00, assumes this works close to its best case.

The case against. China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. The most pessimistic target, $26.20, is roughly what PHG is worth if this bites instead.

Read the full bull and bear case on PHG, including what would have to change to break either one. Walnut is not an investment adviser.

No. Koninklijke Philips N.V. NY Reg (PHG) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Koninklijke Philips N.V. NY Reg's investor relations page or your broker.

• Revenue (TTM): ~EUR 17.7B (2025: ~EUR 17.8B); +0.5% yoy in Q2 2026
• Net income (TTM): ~EUR 1.1B (2025: ~EUR 897M)
• EPS (Q2 2026 vs estimate): 0.56 vs ~0.37
• Operating margin (TTM): ~14%
• Market cap: ~$25B (ADR ~$26.00)
• P/E (trailing / forward): ~19x / ~14x
• Dividend yield: ~4% (~$1.01 per ADR)

At $26.00 on October 16, 2026, Philips trades around 19 times trailing and 14 times forward earnings, about 1.4 times sales, and near 2 times book value, cheaper than a year ago even though profits have recovered. The market is weighing flat sales and a softer second half (consensus Q3 EPS 0.36, down about 13%) against margin gains and fading legal risk. Figures are approximate, reported in euros, and converted to dollars at prevailing rates for the ADR.

Other names that sit close to PHG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PHG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PHG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PHG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

PHG is a way to own a recovering European medical-device leader through a US-listed ADR, with the investment case resting on margin repair, order growth, and how quickly China and past litigation overhangs fade. Recent quarters have beaten earnings estimates, and an October 2026 Dutch court ruling removed one recall-related overhang, but the share price has not followed yet; third-quarter results are due November 3.

Whether PHG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PHG a buy or a sell?, and where the stock could go from here in the PHG stock forecast.

For income investors, whether PHG pays a dividend and how the payout looks is covered in does PHG pay a dividend? And to weigh PHG against a peer, read the full side-by-side comparisons: PHG vs GEHC and PHG vs MDT.